Anti-Infective Drugs Advisory Committee
July 28, 2000
Supplemental new Drug Applications (NDA) 19-537/S038, 19-847/S024, 19-857/S027, 19-858/S021, 20-780/S008 for Cipro (ciprofloxacin), Bayer Corporation, Pharmaceutical Division
Slides
How we got here, What is Different, Diane Murphy MD pdf ppt htm
Bayer Pharmaceutical Division, Andrew S Verderame ppt htm
Anthrax Clinical Disease and Epidemiology, Martin Hugh-Jones, DVM pdf ppt htm
Human pathology Inhalational Disease, David Walker MD pdf
Additional slides
Non-Human Primate Model of Inhalational Anthrax, Arthur Friedlander MD pdf ppt htm
FDA Presentation: FDA's Perspective, Gary K Chikami, MD pdf
Ciprofloxacin for Prophylaxis of Clinical Disease Due to Inhaled B. anthracis, Andrea Meyerhoff MD MSc DTMH pdf ppt htm